Ozempic vs Wegovy Coverage: Why Insurance Treats Them Differently

Key Takeaways

• Same Drug, Different Approvals: Ozempic and Wegovy both contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes, while Wegovy is approved for chronic weight management and cardiovascular risk reduction.
• Indication Drives Coverage: Insurance coverage is almost entirely determined by the FDA-approved indication. Most plans cover Ozempic for diabetes but exclude Wegovy for weight loss.
• "Off-Label" Use Is Not Covered: Prescribing Ozempic for weight loss is considered "off-label" and is rarely covered by any insurance plan.
• Medicare Is Restricted by Law: Federal law prohibits Medicare Part D from covering drugs for weight loss, but Wegovy's new cardiovascular indication has created a limited pathway for coverage.
• Prior Authorization Is Universal: Expect prior authorization requirements for both drugs as insurers try to control costs and prevent off-label use.

Quick Answer

Insurance companies treat Ozempic and Wegovy differently because they are approved for different medical conditions. Ozempic is FDA-approved to treat type 2 diabetes, a condition universally recognized as medically necessary to cover. Wegovy is approved for chronic weight management, which many insurance plans historically classify as a "lifestyle" issue and explicitly exclude from coverage. Even though they contain the same active ingredient (semaglutide), your diagnosis determines which drug your insurance will consider covering. Using Ozempic for weight loss is considered "off-label" and is almost always denied.

In This Article

The Core Issue: Same Drug, Different Jobs

It is one of the most common and frustrating questions for patients: "If Ozempic and Wegovy are both semaglutide, why does my insurance cover one but not the other?" The answer lies not in the drug itself, but in the job the FDA has approved it to do. [1] [2]

Think of it like this: a powerful engine can be used in a family sedan or a race car. The engine is identical, but its intended use is completely different. In the world of pharmaceuticals, Ozempic is the engine in the family sedan, FDA-approved to manage type 2 diabetes. Wegovy is the same engine in the race car, FDA-approved for chronic weight management in patients with obesity or who are overweight with at least one weight-related health condition.

Insurance plans are built around covering treatments for specific, recognized medical conditions known as indications. For decades, type 2 diabetes has been a standard covered condition across virtually every plan. Obesity, however, has often been excluded from coverage, with treatments sometimes labeled as for "lifestyle" or "vanity" purposes. While this view is slowly changing as the medical community increasingly recognizes obesity as a chronic disease, it remains deeply embedded in the structure of many insurance policies. [3]

Ozempic vs. Wegovy: Head-to-Head Coverage Comparison

The most critical factor for insurance coverage is the on-label indication. The table below breaks down the fundamental differences that drive insurance decisions across every type of plan.

Why Your Plan Denies Wegovy (But Might Approve Ozempic)

When an insurance plan denies Wegovy, it is typically for one of three fundamental reasons. Understanding which one applies to your situation is the first step toward finding a solution.

1. Plan Exclusion for Anti-Obesity Medications (AOMs)

This is the most common and most difficult barrier to overcome. Many employer-sponsored and individual plans have a specific clause in their benefits document that excludes all drugs prescribed for weight management. This is a holdover from an era when obesity was not widely recognized as a chronic disease by the insurance industry. If your plan has this exclusion, no amount of prior authorization paperwork will result in approval. The only recourse is to advocate for your employer to remove the exclusion during the next benefits renewal cycle. [3]

2. Formulary Exclusion

Even if a plan does not have a blanket exclusion for weight loss drugs, Wegovy may simply not be on its list of covered medications (the formulary). Insurers curate their formularies to control costs, and with Wegovy's list price exceeding $1,300 per month, many plans have chosen not to include it. In fact, research from the Health System Tracker found that Wegovy is included in just 1% of Marketplace plan formularies, while Ozempic appears on the vast majority. [5]

3. Failure to Meet Prior Authorization Criteria

If Wegovy is on your plan's formulary, it will almost certainly require prior authorization (PA). This means your doctor must submit documentation proving you meet specific clinical criteria, such as BMI thresholds and the presence of weight-related comorbidities. If the documentation is incomplete, does not match the insurer's specific requirements, or if the insurer's criteria are more restrictive than the FDA label, the claim will be denied.

Ozempic, on the other hand, is almost always on the formulary for treating type 2 diabetes. While it also requires prior authorization, the criteria are straightforward: a confirmed diagnosis of type 2 diabetes, typically supported by A1C lab results. However, as insurers have seen a dramatic surge in off-label Ozempic prescriptions for weight loss, they have significantly tightened PA requirements. Penn LDI research found that prior authorization for diabetes GLP-1s increased from approximately 5% of Medicare beneficiaries in 2023 to nearly 100% by 2025. [6]

Prior Authorization: The Gatekeeper for Both Drugs

Prior authorization has become the primary tool insurers use to manage GLP-1 costs and prevent off-label use. Understanding how PA works differently for each drug is essential for patients and providers.

A critical finding from the Penn LDI research team is that many Medicaid prior authorization policies are more restrictive than the FDA's own criteria. While the FDA label for Wegovy requires only one unspecified weight-related health risk, 70% of state Medicaid PA policies specify which comorbidities qualify, and some require two or more. [4]

Commercial Insurance: What to Expect

For patients with employer-sponsored or individual commercial insurance, the landscape is a patchwork. Coverage depends entirely on the specific plan your employer has chosen and whether it includes an anti-obesity medication benefit.

If You Have Type 2 Diabetes

Ozempic is likely covered. Your doctor will need to submit a prior authorization confirming your T2D diagnosis and A1C levels. Expect a copay ranging from $25 to $150 per month, depending on your plan's formulary tier. You may also be eligible for the Novo Nordisk Savings Card, which can reduce your copay to as low as $25 per fill for up to 24 months.

If You Need Weight Loss Treatment

Check your plan's Summary of Benefits and Coverage (SBC) document. Look specifically for language about "anti-obesity medications," "weight management drugs," or "weight loss medications." If these are listed as excluded, Wegovy will not be covered regardless of your clinical need. If your plan does include a weight management benefit, Wegovy may be available but will require prior authorization and is likely to be placed on a high formulary tier (Tier 4 or 5), resulting in higher copays.

The "Off-Label Ozempic" Trap

Some patients and providers attempt to use Ozempic off-label for weight loss, hoping that its diabetes indication will make it easier to get covered. Insurers are well aware of this practice and have responded by requiring A1C lab results as part of the prior authorization process. If your A1C is below the diabetic threshold (typically 6.5%), the claim will be denied. Submitting false lab results to obtain coverage constitutes insurance fraud and carries serious legal consequences.

The Medicare Dilemma: The Law vs. New Evidence

For Medicare beneficiaries, the situation is even more complex due to a specific federal statute. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Part D plans from covering drugs "used for anorexia, weight loss, or weight gain." [7]

This created a clear and seemingly immovable divide:

The November 2025 White House deal with Novo Nordisk set a Medicare price of $245 for both Ozempic and Wegovy (down from list prices of $968 and $1,349 respectively), with a patient out-of-pocket cap of $50 per month. However, this price only applies when the drug is covered by Medicare, which still excludes Wegovy for weight loss. [8]

Additionally, the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending provides further protection for Medicare beneficiaries who do have covered GLP-1 prescriptions.

Medicaid: A State-by-State Patchwork

Medicaid coverage for GLP-1 medications varies dramatically by state, creating significant disparities in access based on geography.

Most state Medicaid programs cover GLP-1s approved for diabetes, including Ozempic. However, coverage for weight-loss versions like Wegovy remains severely limited. As of June 2024, only 13 states covered GLP-1s for weight loss in adults through their fee-for-service Medicaid programs, and most of those required prior authorization with criteria more restrictive than the FDA label. [4]

The situation has become even more challenging in some states. Pennsylvania, for example, eliminated Medicaid coverage of GLP-1s for weight loss starting in January 2026, abruptly disrupting care for patients who were already benefiting from treatment. Other states may follow suit as they grapple with the budget impact of these medications. [6]

The Wegovy CV Indication: A Game-Changer

In March 2024, the FDA approved a landmark new indication for Wegovy: to reduce the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease and either obesity or overweight. This approval was based on the results of the SELECT trial, which demonstrated a 20% reduction in major cardiovascular events. [9]

This was a game-changer for insurance coverage because it gave Wegovy a purpose beyond weight loss. Because the drug is now approved for cardiovascular risk reduction, CMS issued guidance allowing Medicare Part D plans to cover Wegovy for this specific indication. Coverage for weight loss alone remains prohibited by law.

For patients, this means that if you have both established cardiovascular disease and obesity or overweight, you may now be eligible for Medicare coverage of Wegovy. Your cardiologist or primary care physician would need to document the cardiovascular indication in the prior authorization request, rather than framing it as a weight loss prescription.

The Future: The Treat and Reduce Obesity Act (TROA)

There is a bipartisan effort in Congress to fundamentally change the Medicare law that blocks coverage of anti-obesity medications. The Treat and Reduce Obesity Act (TROA), if passed, would amend the Social Security Act to authorize Medicare Part D coverage for FDA-approved anti-obesity medications, including Wegovy. [10]

The bill has widespread support from major medical organizations, including the Endocrine Society, the American Medical Association, and the Obesity Action Coalition. [11] Proponents argue that covering these medications would reduce long-term healthcare costs by preventing obesity-related complications such as heart disease, stroke, type 2 diabetes, and certain cancers.

However, the Congressional Budget Office (CBO) has estimated that expanding Medicare coverage to include anti-obesity medications would carry a significant cost. As of early 2026, the bill has not yet been passed into law, and the April 2025 CMS final rule for Contract Year 2026 did not include anti-obesity medication coverage. The legislative path forward remains uncertain.

What You Can Do Right Now

Regardless of your insurance situation, there are concrete steps you can take to improve your chances of getting coverage or to reduce your out-of-pocket costs.

Download: Insurance Appeal Checklist

If your Wegovy prescription has been denied, our step-by-step checklist walks you through the documents and process needed for a successful appeal, including tips for requesting a peer-to-peer review.

Frequently Asked Questions

References

1. FDA. Ozempic (semaglutide) Prescribing Information. Revised 2023.
2. FDA. Wegovy (semaglutide) Prescribing Information. Revised 2023.
3. WebMD. Wegovy: When Insurance Won't Cover Your Meds. June 2024.
4. Klebanoff MJ, et al. Medicaid Coverage and Prior Authorization for Antiobesity GLP-1 Receptor Agonists. Penn LDI / JAMA. January 2026.
5. Health System Tracker. Insurer Strategies to Control Costs Associated with Weight Loss Drugs. June 2024.
6. Klebanoff MJ, et al. Medicare Part D Coverage and Costs for GLP-1 Receptor Agonists. Penn LDI. January 2026.
7. Social Security Act §1862(a)(1)(J). Exclusions from Coverage.
8. White House Fact Sheet. Most Favored Nation Pricing for Ozempic, Wegovy, Mounjaro, and Zepbound. November 2025.
9. FDA. FDA Approves First Treatment to Reduce Risk of Heart Attack, Stroke and Cardiovascular Death in Adults with CVD and Obesity/Overweight. March 2024.
10. Congress.gov. H.R.4818 — Treat and Reduce Obesity Act of 2023.
11. Endocrine Society. Endocrine Society Endorses Treat and Reduce Obesity Act. June 2025.

Related Guides

• Ozempic Cost in 2026: With vs Without Insurance (Copay, Cash Price, Savings)
• Wegovy Cost in 2026: Insurance Coverage, Savings Programs, and Out-of-Pocket Estimates
• How to Get Wegovy for Weight Loss: Eligibility, Prior Authorization, and Common Denials
• Rybelsus Cost & Coverage: What's Different About the Oral Form of Semaglutide